Data / Form D filings / Lenz Therapeutics, Inc.
Lenz Therapeutics, Inc.: Form D filings
Lenz Therapeutics, Inc., a biotechnology company in Del Mar, CA, filed 5 Form D notices with the SEC between 2016 and 2023. The latest, on March 10, 2023, reports $83.5 million sold of a $83.5 million offering to 27 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 445 MARINE VIEW AVE., SUITE #320, Del Mar, CA, 92014
- Phone
- (619) 890-5125
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1678518
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | New notice | $83,499,961 | $83,499,961 | 27 | Mar 6, 2023 | sec.gov | |
| Nov 22, 2022 | Amendment | $49,002,348 | $49,002,348 | 45 | Oct 30, 2020 | sec.gov | |
| Nov 9, 2020 | New notice | $68,250,000 | $1,751,193 | $66,498,807 | 30 | Oct 30, 2020 | sec.gov |
| Sep 14, 2020 | New notice | $250,000 | $250,000 | 25 | Aug 5, 2020 | sec.gov | |
| Jun 30, 2016 | New notice | $3,400,000 | $3,399,989 | $11 | 45 | Jun 3, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Evert Schimmelpennink | Executive Officer, Director | |
| James McCollum | Director | |
| Clare Ozawa | Director | |
| Zach Scheiner | Director | |
| Stefan Larson | Director | |
| Frederic Guerard | Director | |
| Chris Dimitropoulos | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Mar 6, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lenz Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.